CRWD vs PFE: Which Is the Better Buy?
Side-by-side comparison of CrowdStrike Holdings, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-25.
CrowdStrike Holdings, Inc. · Technology
$259.67
-13.1% upside to fair value
Low Conviction
Grade C
High Quality
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+12.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CRWD |
PFE |
| Current Price |
$259.67 |
$27.64 |
| Fair Value Estimate |
$225.56 |
$30.94 |
| Upside to Fair Value |
-13.1%
|
+12.0%
|
| Market Cap |
$264.4B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
595.7x
|
17.4x
|
| Price / Sales |
49.0x
|
2.5x
|
| Price / FCF |
167.9x
|
14.3x
|
| Revenue Growth YoY |
+25.8%
|
+2.6%
|
| Gross Margin |
75.2%
|
71.3%
|
| Operating Margin |
-2.2%
|
25.1%
|
| Return on Equity |
1.3%
|
4.9%
|
| Dividend Yield |
0% |
6.22% |
| FCF Yield |
0.6%
|
6.97%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
CrowdStrike Holdings is a cloud-native cybersecurity platform company that sells subscriptions to its Falcon platform and a growing array of cloud modules spanning endpoint protection, cloud workload security, identity protection, Next-Gen SIEM, threat intelligence, and managed services, generating revenue through a direct sales force and channel partners from its Austin, Texas headquarters with …
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
CRWD |
PFE |
| Zone Low |
$169.17 |
$23.21 |
| Zone High |
$191.73 |
$26.30 |
| In Buy Zone? |
No
|
No
|